Germ Cell Tumor and Testicular Tumor DNA Registry
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 26, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Germ Cell Tumor and Testicular Tumor DNA Registry is a study designed to gather important information about germ cell tumors (GCT) and testicular tumors. Researchers want to understand more about these tumors to improve prevention, diagnosis, treatment, and outcomes. The registry will include people diagnosed with these tumors, as well as their family members and healthy individuals who do not have a personal history of cancer. By studying both groups, the researchers hope to learn why some people develop these tumors while others do not.
To participate in this study, you need to be at least 18 years old and speak English. If you have a germ cell tumor or testicular mass, you can join the study. Family members of those diagnosed with these tumors are also welcome, even if they are healthy. On the other hand, if you are healthy and have no family history of these tumors, you can join as a control participant. Throughout the study, participants may be asked to provide information about their health and may undergo tests to help researchers learn more about these conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Case Cohort
- • Must be ≥ 18 years of age AND
- • Must be an English-speaker AND
- • Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass
- • Family Member Cohort
- • Must be ≥ 18 years of age AND
- • Must be an English-speaker AND
- • Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.
- • Control Cohort
- • Must be ≥ 18 years of age AND
- • Must be an English-speaker AND
- • Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND
- • Must not have a family history of germ cell tumor or testicular tumor AND
- • Must not be a blood relative of controls enrolled in this study
- Exclusion Criteria:
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Commack, New York, United States
Basking Ridge, New Jersey, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
Basking Ridge, New Jersey, United States
Cold Spring Harbor, New York, United States
Patients applied
Trial Officials
Darren Feldman, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials